Streetbeat News

ELEV

Elevation Oncology, Inc.

https://elevationoncology.com

Industry

Biotechnology

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Open

0.60

Mkt cap

36M

Volume

481K

High

0.62

P/E Ratio

-0.76

52-wk high

5.83

Low

0.57

Div yield

N/A

52-wk low

0.44

Elevation Oncology reported a Q2 2024 GAAP EPS of $(0.18), which beats the estimated $(0.22).

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:24 am

Elevation Oncology has reported initial data from the dose escalation portion of its ongoing Phase 1 clinical trial of EO-3021. The trial showed a 42.8% confirmed objective response rate (ORR) in a subset of patients with Claudin 18.2-enriched gastric and GEJ cancer. The company observed minimal MMAE-associated toxicities and plans to advance into monotherapy dose expansion and combination cohorts, with additional data expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:18 am

GeneDx Holdings Corp. (NASDAQ:WGS) has led the Russell 2000 Index in 2024 with a 1,101% increase in share price, driven by a shift to more comprehensive genetic testing. Goldman Sachs has raised its price target for GeneDx from $12.50 to $28, maintaining a Neutral rating. Other top performers include Corbus Holdings Inc. (NASDAQ:CRBP) and Root, Inc. (NASDAQ:ROOT).

Portfolio Pulse from Michael Juliano

July 18, 2024 | 5:36 pm

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:46 pm

JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 2:39 pm

Elevation Oncology plans to expand its Phase 1 trial to include two combination cohorts evaluating EO-3021 for advanced gastric or gastroesophageal junction cancer. The company expects to initiate dosing by the end of 2024, following clinical supply agreements with Eli Lilly and GSK.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 11:32 am

Piper Sandler has initiated coverage on Elevation Oncology (NASDAQ:ELEV) with an Overweight rating and a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 9:56 am

Stephens & Co. analyst Sudan Loganathan initiates coverage on Elevation Oncology (NASDAQ:ELEV) with an Overweight rating and a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:13 am

The article reports on the performance of health care stocks in Monday's after-market session, highlighting significant gainers and losers. Notably, Aesthetic Medical Intl, Harrow, and Vaxart experienced upward movements, attributed to recent earnings releases for some. Conversely, Augmedix, Akoya Biosciences, and Calidi Biotherapeutics saw notable declines, also influenced by their earnings reports.

Portfolio Pulse from Benzinga Insights

May 13, 2024 | 8:31 pm

Wedbush analyst Robert Driscoll reiterated an Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 1:38 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.